Importantly, carriers of rare CFH and CFI variants are eligible candidates for ongoing complement trials for AMD targeting specific genotypes (https://www.clinicaltrialsregister.eu/ctr-search/trial/2019–003421–22/GB, https://clinicaltrials.gov/ct2/show/study/NCT04246866) and for potential future treatments. The gene discussed is CFH; the disease is age-related macular degeneration.